Brigitte Dréno - Concepedia

Author

Brigitte Dréno

Inserm ORCID

Also Known As

A. Khammari, B DRENO, B Dreno, B Drèno, B Dréno, B. DRENO, B. DRÉNO, B. Dreno, B. Dréno, B. R. I. Dreno

1.5K

Publications

66.2K

Citations

104

H-Index

273

Concepts

All Affiliations

Inserm Nantes Université Centre Hospitalier Universitaire de Nantes Centre d'Investigation Clinique de Nantes Centre de Recherche en Cancérologie et Immunologie Intégrée Nantes Angers

About

Brigitte Dréno is an author at Inserm specializing in medicine, dermatology, and immunology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	54	182	14.3K
2	Health Sciences	14	16	1K
3	Engineering	4	4	156
4	Education	1	1	19
5	Language Studies	1	1	12

Brigitte Dréno

418

Publications

52.1K

Citations

H-Index

Page 1

	Year	Citations
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma James Larkin, Vanna Chiarion‐Sileni, René González, New England Journal of Medicine	2015	8K
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation Paul B. Chapman, Axel Hauschild, Caroline Robert, New England Journal of Medicine	2011	7.6K
Improved Survival with MEK Inhibition in BRAF-Mutated Melanoma Keith T. Flaherty, Caroline Robert, Peter Hersey, New England Journal of Medicine	2012	2.1K
Combined Vemurafenib and Cobimetinib in <i>BRAF</i> -Mutated Melanoma James Larkin, Paolo A. Ascierto, Brigitte Dréno, New England Journal of Medicine	2014	2K
Improved survival with MEK Inhibition in BRAF-mutated melanoma for the METRIC Study Group Keith T. Flaherty, Caroline Robert, Peter Hersey, Zurich Open Repository and Archive (University of Zurich)	2012	1.3K
Randomized Phase III Study of Temozolomide Versus Dacarbazine in the Treatment of Patients With Advanced Metastatic Malignant Melanoma Mark R. Middleton, Jean‐Jacques Grob, Neil K. Aaronson, Journal of Clinical Oncology	2000	1.3K
Cobimetinib combined with vemurafenib in advanced BRAFV600-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial Paolo A. Ascierto, Grant A. McArthur, Brigitte Dréno, The Lancet Oncology MedicineAdvanced Brafv600-mutant MelanomaMelanomaImmune Checkpoint InhibitorDermatology	2016	986
Safety and efficacy of vemurafenib in BRAFV600E and BRAFV600K mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study Grant A. McArthur, Paul B. Chapman, Caroline Robert, The Lancet Oncology MedicineMelanomaImmunologyBrafv600k Mutation-positive MelanomaCancer Treatment	2014	969
Phase III Randomized Clinical Trial Comparing Tremelimumab With Standard-of-Care Chemotherapy in Patients With Advanced Melanoma Antoni Ribas, Richard Kefford, Margaret Marshall, Journal of Clinical Oncology	2013	811
Effect of long-term immunosuppression in kidney-graft recipients on cancer incidence: randomised comparison of two cyclosporin regimens Jacques Dantal, Maryvonne Hourmant, Diego Cantarovich, The Lancet Transplant RejectionUrologyTransplantationKidney TransplantMedicine	1998	742

Page 1